Evidence map›Paper›PMID 29707131›Full record

ArticleOncotarget2018

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

David S Moura, Rafael Ramos, Antonio Fernandez-Serra, Teresa Serrano, Julia Cruz, Ramiro Alvarez-Alegret, Rosa Ortiz-Duran, Luis Vicioso, Maria Luisa Gomez-Dorronsoro, Xavier Garcia Del Muro and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Prognostic Impact ofCancers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 1 country.

David S MouraInstitute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
Rafael RamosPathology Department, Son Espases University Hospital, Palma, Illes Baleares, Spain.
Antonio Fernandez-SerraLaboratory of Molecular Biology, Valencian Oncologic Institute, Valencia, Spain.
Teresa SerranoPathology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Julia CruzPathology Department, Valencian Oncologic Institute, Valencia, Spain.
Ramiro Alvarez-AlegretPathology Department, Miguel Servet University Hospital, Zaragoza, Spain.
Rosa Ortiz-DuranPathology Department, Josep Trueta University Hospital, Girona, Spain.
Luis ViciosoPathology Department, Virgen de la Victoria University Hospital, Malaga, Spain.
Maria Luisa Gomez-DorronsoroPathology Department, Hospital Complex of Navarra, Pamplona, Spain.
Xavier Garcia Del MuroMedical Oncology Department, Institut Català d'Oncologia, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
Javier Martinez-TruferoMedical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain.
Jordi Rubio-CasadevallMedical Oncology Department, Catalan Oncologic Institute, Josep Trueta University Hospital, Girona, Spain.
Isabel SevillaMedical Oncology Department, Virgen de la Victoria University Hospital, Malaga, Spain.
Nuria LainezMedical Oncology Department, Hospital Complex of Navarra, Pamplona, Spain.
Antonio GutierrezHematology Department, Son Espases University Hospital, Palma, Illes Baleares, Spain.
Cesar SerranoMedical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Maria Lopez-AlvarezInstitute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
Nadia HindiInstitute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
Miguel TaronInstitute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
José Antonio López-GuerreroLaboratory of Molecular Biology, Valencian Oncologic Institute, Valencia, Spain.
Javier Martin-BrotoInstitute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla), Sevilla, Spain.
Instituto de Biomedicina de Sevilla · ESComplejo Hospitalario de Navarra · ESHospital Clínico Universitario Virgen de la Victoria · ESHospital Universitari de Girona Doctor Josep Trueta · ESHospital Universitario Miguel Servet · ESHospital Universitario Son Espases · ESBellvitge University Hospital · ESFundación Instituto Valenciano de Oncología · ESHospital Universitario Virgen del Rocío · ESInstitut Català d'Oncologia · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are limited findings available on KIT-negative GIST-like (KNGL) population. Also, KIT expression may be post-transcriptionally regulated by miRNA221 and miRNA222. Hence, the aim of this study is to characterize KNGL population, by differential gene expression, and to analyze miRNA221/222 expression and their prognostic value in KNGL patients.

methods

resultsHierarchical cluster analyses from gene expression data identified two groups: group I had

conclusionsWe identified two distinct KNGL subsets, with a different prognostic value. Increased levels of miRNA221/222, which are associated with worse OS, could explain the absence of KIT protein expression of most KNGL tumors.

Indexed as

DOG1IGF1RKITKNGLmiRNA221/222 cluster

Identifiers

PMID29707131
PMCPMC5915139
OpenAlexW2796313720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.